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Impella and IABP for high-risk PCI: a systematic review and meta-analysis
SHAIKH Anum (1), SHAIKH Anum (1), MARTIN Antony P. (1), PEDRA Gabriel (1), O’HARA Jamie (1,2), WOLLNY Mathias (3), 
GOETZENICH Andreas (3), HILL Jonathan (4)
Aims: A systematic literature review (SLR) and meta-analysis was undertaken to compare health outcomes associated with the use of 
Impella and intra-aortic balloon pump (IABP) in patients undergoing high-risk percutaneous coronary intervention (HR PCI).
Methods and results: A SLR of published randomised and non-randomised studies from Sep 1999-2019 (20 years) was undertaken through 
a search of MEDLINE®, Web of Science, Cochrane Library, and Scopus. Forward and backward citation searching was conducted using 
Google Scholar and supplemented with a search of the grey literature. For studies which met the inclusion criteria, data extracted included 
respondent characteristics, study design, and the reporting of mortality, myocardial infarction, complication rates, and other clinical 
outcomes. A comparison of clinical outcomes was synthesized using a meta-analysis and a random-effects model was fitted to account for 
heterogeneity between studies. Small study effect, including publication bias, was tested using funnel plots and Egger’s test. Meta-analyses 
of patient subgroups were also conducted where data permitted. Of 638 titles and abstracts screened, 22 studies met the study inclusion 
criteria. Studies tended to report superior health outcomes for patients who received Impella compared to IABP in terms of lower mortality, 
major bleeding, vascular complications, revascularisation, stroke/transient ischaemic attack, renal complications, and major adverse 
cardiovascular events (MACE)/major adverse cardiovascular and cerebrovascular events (MACCE). Although funnel plots were not 
always found to be symmetrical, no evidence of publication bias (with the exception of the IABP pooled MACE/MACCE (p=0.033) 
outcome) was found with the Egger’s test (p>0.05).
Conclusions: The results of our SLR and meta-analysis indicate that Impella is associated with superior health outcomes when compared 
to IABP in terms of mortality, major bleeding, vascular complications, revascularisation, stroke/ transient ischaemic attack, renal 
complications, and MACE/MACCE. Further research is needed to explore the conclusions regarding the presence of publication bias with 
the IABP pooled MACE/MACCE outcome. Moreover, further studies and/ or real-world data (RWD) are needed to confirm and identify 
the optimal approach for patients undergoing HR PCI in clinical practice. This will enable the aforementioned patients to gain maximal 
health status by using available resources.
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